昆明医科大学学报2012，Vol.33Issue(12)：87-90,4.
阿德福韦酯与聚乙二醇干扰素α-2a联合治疗HBeAg阳性慢性乙肝
Efficacy of IFN α-2a Combined with Adefovir Dipivoxil in the Treatment of HbeAg Positive Chronic Hepatitis B
杨永锐 1李晖1
作者信息
- 1. 昆明市第三人民医院,云南昆明650041
- 折叠
摘要
Abstract
Objective To investigate whether the combination therapy of pegylated IFN α -2a plus adefovir dipivoxil (ADV) improve the efficacy of the treatment in CHB patients with HBeAg positive or not. Methods 120 CHB patients with HBeAg positive who received 48-week pegylated IFNa-2a therapy were enrolled into this study. If serum HBV DNA levels exceeded 1000 copies/mL at week 24, the patients were assigned to group A (pegylated IFN-α 2a plus ADV, 35 eases) or group B (pegylated IFN α-2a only, 35 cases) ; otherwise, they received the unceasing monotherapy of pegylated IFNa-2a (group C, 50 cases). Results At week 48, HBeAg seroconversion rates were 25.7% , 20.0% and 66.0% , but rates of aminotransferases normalization and HBV DNA suppression ( < 1 000 copies/mL) were not statistically significant among three groups. But during week 24 to week 48, rates of HBeAg seroconversion, aminotransferases normalization and HBV DNA suppression had no statistically significant difference between group A and B. Conclusion An ADV add-on therapy in pegylated IFNa-2a treatment seems able to improve the inhibition of HBV DNA in chronic hepatitis B patients with positive HBeAg.关键词
乙型/肝炎/阿德福韦酯/聚乙二醇干扰素α-2a/乙肝治疗Key words
Hepatitis B:Adefovir dipivoxil:Interferon Alfa-2 α :Hepatitis therapy分类
医药卫生引用本文复制引用
杨永锐,李晖..阿德福韦酯与聚乙二醇干扰素α-2a联合治疗HBeAg阳性慢性乙肝[J].昆明医科大学学报,2012,33(12):87-90,4.
